# Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

> **NCT06736379** · PHASE1 · RECRUITING · sponsor: **VLP Therapeutics** · enrollment: 41 (estimated)

## Conditions studied

- Head and Neck Cancers- Squamous Cell
- Head and Neck Cancer
- Solid Tumors
- HNSCC
- SCC - Squamous Cell Carcinoma
- SCCHN
- Head Neck Cancer
- Head and Neck Squamous Cell Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Squamous Cell Carcinoma, Head And Neck
- Squamous Cell Head and Neck Carcinoma
- Oral Cavity
- Oral Cavity Carcinoma

## Interventions

- **BIOLOGICAL:** VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection)
- **DRUG:** Pembrolizumab (KEYTRUDA®)
- **BIOLOGICAL:** VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection)

## Key facts

- **NCT ID:** NCT06736379
- **Lead sponsor:** VLP Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-13
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06736379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06736379, "Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06736379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*